Predictive Technology Group

Predictive Technology Group, Inc. engages in the development and commercialization of discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic and human cells, tissues, and human cellular and tissue-based products. The company is headquartered in Salt Lake City, Utah and currently employs 62 full-time employees. The company went IPO on 2007-07-11. The Company, through its subsidiaries, is focused on specific points of the care continuum, including detection, prevention and treatment. Predictive Analytics, Predictive Laboratories, and Predictive Biotech each bring critical solutions to personalized patient care by leveraging its research, genomics, genetic library and expertise in developing bioscience solutions. Predictive Analytics is the repository for its genetic library. Predictive Biotech provides regenerative medicine. Its products are derived from tissue sources rich in properties that support the body’s natural ability to heal itself. All products are safely, ethically and minimally processed to deliver allografts that preserve the naturally occurring characteristics and factors of the donor tissue. Its research and use of processing methods has propelled its placental-derived and Wharton’s Jelly umbilical cord-derived products to new heights.